Botanical species · safety record

Streblus asper

The EFSA Compendium of Botanicals holds 24 constituent measurements and 1 adverse-effect record for Streblus asper. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Streblus asper Lour.

24Constituent measurements

1Safety records

14Cited sources

0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Alkaloids	Bark	Solvent extraction	—	Phytochemical screening	Resolve DOI
Asperosid	Bark	Solvent extraction	—	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	Resolve DOI
Cardiac glycosides	Bark	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Honokiol	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Isoflavones	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Lignans	Bark	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Lignans	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Lignans	Wood	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Magnolol	Bark	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Magnolol	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Neolignans	Bark	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Neolignans	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Strebloside	Bark	Solvent extraction	—	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	Resolve DOI
Asperosid	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Carboline alkaloids	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Cardiac glycosides	Bark	Solvent extraction	—	Chromatographic tests	No resolvable identifier
Cardiac glycosides	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Magnolol	Leaves	—	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Naphthoquinones	Bark	—	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Pregnane derivatives	Bark	—	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Salicylic acid	Leaves	—	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Saponins	Roots and other underground parts	Solvent extraction	—	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	No resolvable identifier
Strebloside	Bark	Solvent extraction	—	Chromatographic tests	No resolvable identifier
Strebloside	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Systemic	Cardiovascular / haematological	Leaves	Solvent extraction	House mouse (as animal)	Short-term toxicity	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Kumar, R. B. Suresh., Puratchikodi, A., Prasanna, Angelene., Dolai, Narayan., Majumder, Piyali., Mazumder, U. K., Haldar, P. K. Pre clinical studies of Streblus asper Lour in terms of behavioural safety and toxicity . Oriental pharmacy and experimental medicine, 2011, vol. 11, no. 4, p. 243-249.
PRAKASH, K., DEEPAK, D., KHARE, A., KHARE, MP. A PREGNANE GLYCOSIDE FROM STREBLUS-ASPER. Phytochemistry, 1992, vol. 31, no. 3, p. 1056-1057.
CHATTERJEE, RK., FATMA, N., MURTHY, PK., SINHA, P., KULSHRESTHA, DK., DHAWAN, BN. MACROFILARICIDAL ACTIVITY OF THE STEMBARK OF STREBLUS-ASPER AND ITS MAJOR ACTIVE CONSTITUENTS . Drug development research, 1992, vol. 26, no. 1, p. 67-78. DOI
Chaturvedi, SK. Saponin from Streblus asper roots. Asian journal of chemistry, 2005, vol. 17, no. 1, p. 637-637.
Chen, Zizhan., Li, Jun., Wu, Qiang., Yang, Ruiyun., Li, Luqing., Li, Shan., Huang, Jiguo. Chemical constituents and antiphlogistic activity of the bark of Streblus asper. Guangxi zhiwu, 2011, vol. 31, no. 6, p. 849-852.
Li, Jun., Huang, Yan., Guan, Xin-Lan., Li, Jian., Deng, Sheng-Ping., Wu, Qiang., Zhang, Yan-Jun., Su, Xiao-Jian., Yang, Rui-Yun. Anti-hepatitis B virus constituents from the stem bark of Streblus asper. Phytochemistry, 2012, vol. 82, p. 100-109. DOI
Ren, Yulin., Chen, Wei-Lun., Lantvit, Daniel D., Sass, Ellen J., Shriwas, Pratik., Tran Ngoc Ninh., Chai, Hee-Byung., Zhang, Xiaoli., Soejarto, Djaja D., Chen, Xiaozhuo., Lucas, David M., Swanson, Steven M., Burdette, Joanna E., Kinghorn, A. Douglas. Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity . Journal of natural products, 2017, vol. 80, no. 3, p. 648-658. DOI
Lu, Xuewen., Li, Jun., Huang, Cuiping., Meng, Aiping., Zhu, Shengjun. Chemical constituents in leaves of streblus asper. Guangxi shifan daxue xuebao, ziran kexueban, 2009, vol. 27, no. 4, p. 61-64.
Hano, Y., Juma, P., Abliz, Z., Sun, HD., Nomura, T. Two new cardenolide glycosides from Streblus asper. Heterocycles, 2003, vol. 59, no. 2, p. 805-809.
Chen, Hong., Li, Jun., Wu, Qiang., Niu, Xiao-Tao., Tang, Mao-Tong., Guan, Xin-Lan., Li, Jian., Yang, Rui-Yun., Deng, Sheng-Ping., Su, Xiao-Jian. Anti-HBV activities of Streblus asper and constituents of its roots. Fitoterapia, 2012, vol. 83, no. 4, p. 643-649. DOI
Li, Jun., Meng, Ai-Ping., Guan, Xin-Lan., Li, Jian., Wu, Qiang., Deng, Sheng-Ping., Su, Xiao-Jian., Yang, Rui-Yun. Anti-hepatitis B virus lignans from the root of Streblus asper. Bioorganic & medicinal chemistry letters, 2013, vol. 23, no. 7, p. 2238-2244. DOI
Li, Jun., Zhang, Yan-Jun., Jin, Bai-Feng., Su, Xiao-Jian., Tao, Yi-Wen., She, Zhi-Gang., Lin, Yong-Cheng. (1)H and (13)C NMR assignments for two lignans from the heartwood of Streblus asper . Magnetic resonance in chemistry, 2008, vol. 46, no. 5, p. 497-500. DOI
Verma, Vandana., Tripathi, Avinash C., Saraf, Shailendra K. Bioactive non-sterol triterpenoid from Streblus asper: microwave-assisted extraction, HPTLC profiling, computational studies and neuro-pharmacological evaluation in BALB/c mice . Pharmaceutical biology, 2016, vol. 54, no. 11, p. 2454-2464. DOI
Liang, Chengqin., Zhou, Xianli., Wang, Zheng., Su, Xiaojian., Xu, Qing. Chemical constituents from the leaves of Streblus asper. Zhongchengyao, 2010, vol. 32, no. 5, p. 824-827.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature